开发创新药管线,是为了出售还是自用?投资者已经给出了答案。作者:储旻华去年初,本人估计2025年中国药企的授权交易会相对平稳,非上市企业的融资会日益艰难。出乎意料之外,去年授权交易和融资双双创下新高。除了资产授权,去年创新药方面的研发合作,尤其是与海外公司的合作迅猛增长,成为继资产授权以外中国药企海外交易又一重要路径。异常活跃的授权和研发合作交易绝大多数为中国药企与海外制药公司的交易。...
Source Link开发创新药管线,是为了出售还是自用?投资者已经给出了答案。作者:储旻华去年初,本人估计2025年中国药企的授权交易会相对平稳,非上市企业的融资会日益艰难。出乎意料之外,去年授权交易和融资双双创下新高。除了资产授权,去年创新药方面的研发合作,尤其是与海外公司的合作迅猛增长,成为继资产授权以外中国药企海外交易又一重要路径。异常活跃的授权和研发合作交易绝大多数为中国药企与海外制药公司的交易。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.